A Phase 1 Study of HS-10342 In Patients With Advanced Solid Tumor
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this
study is to investigate the safety/tolerability and the pharmacokinetic profile of HS-10342
in Chinese advanced solid tumor patients. Preliminary efficacy will be also investigated in
this study.